Bridge Biotherapeutics, Inc.

General Information
Company Name
Bridge Biotherapeutics, Inc.
Founded Year
2015
Location (Offices)
Korea South +2
Founders / Decision Makers
Number of Employees
30
Industries
-
Funding Stage
-
Social Media

Bridge Biotherapeutics, Inc. - Company Profile

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.

Funding Rounds & Investors of Bridge Biotherapeutics, Inc. (0)

View All

There is no investment information

Latest News of Bridge Biotherapeutics, Inc.

View All

No recent news or press coverage available for Bridge Biotherapeutics, Inc..

Similar Companies to Bridge Biotherapeutics, Inc.

View All
Morphic Therapeutic - Similar company to Bridge Biotherapeutics, Inc.
Morphic Therapeutic Wholly owned subsidiary of Eli Lilly and Company
Palisade Bio - Similar company to Bridge Biotherapeutics, Inc.
Palisade Bio Late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications
Digestive Health Center - Similar company to Bridge Biotherapeutics, Inc.
Digestive Health Center Comprehensive care and advanced treatment for all your digestive health needs.